At a glance
ClinicalIndex Comparison RecordN/ACompleted· 102 enrolled
Drug / intervention
Fragmin (dalteparin sodium )drug
Likely dose
Fragmin (dalteparin sodium ) 200 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fragmin Safety And Efficacy In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism And Extended Thromboprophylaxis In Cancer Patients In Slovakia (An Open, Prospective, Non-Comparative Study)
In Brief
An observational study evaluating Fragmin (dalteparin sodium ) for Acute Deep Vein Thrombosis. Completed, enrolled 102 participants.
Detailed Summary
To collect postmarketing data about Fragmin safety and efficacy in the treatment of deep vein thrombosis with or without pulmonary embolism in cancer patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Deep Vein Thrombosis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJun 2007
Primary CompletionJun 2009
TodayJul 2026
First PostedMay 31, 2007
Enrollment StartJun 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.1 years ago
Interventions
Fragmin (dalteparin sodium )drug
Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.